Polymeric, injectable, intravitreal hydrogel devices for posterior segment applications and interventions.

Area of Science:

• Ophthalmology
• Biomaterials Science
• Drug Delivery Systems

Background:

• Posterior segment eye diseases can lead to blindness and often require long-term treatment.
• The eye's unique structure, including blood-ocular barriers, presents significant challenges for effective drug delivery.
• Age-related macular degeneration exemplifies a condition necessitating chronic intravitreal therapeutic interventions.

Purpose of the Study:

• To review biodegradable and non-biodegradable injectable intravitreal polymeric hydrogel devices.
• To analyze the composition and impact of various polymeric components on device performance.
• To discuss therapeutic agents and explore future directions using intelligent polymeric systems.

Main Methods:

• Review of existing literature on polymeric hydrogel formulations for intravitreal injection.
• Analysis of material properties of polymers such as poly(ethylene glycol), PLGA, silica, hyaluronic acid/dextran, silk, chitosan/alginate, and PNIPAM.
• Examination of therapeutic agents including ranibizumab, dexamethasone, bevacizumab, and aflibercept.

Main Results:

• Various polymeric hydrogels show potential for sustained drug release in the posterior segment.
• Material properties significantly influence the efficacy and safety of intravitreal devices.
• Combination of specific polymers and therapeutic agents can enhance treatment outcomes.

Conclusions:

• Injectable polymeric hydrogels represent a promising strategy for optimizing drug delivery to the posterior segment of the eye.
• Intelligent polymeric systems offer potential for responsive and targeted drug release, improving treatment for chronic conditions.
• Further research into novel biomaterials and drug combinations is essential for advancing intravitreal therapies.